Regular readers of this blog know that one way to measure the worth of an executive to a publicly held company is to watch the stock price.
After the market closed Monday, Endo Pharmaceuticals Holdings Inc. announced that its president and CEO, Peter A. Lankau, would resign as of March 1.
A spokesman had told Inquirer staff writer Linda Loyd last night that Lankau and the board "weren't in total sync." Looks like the market agrees.
Endo shares were up 9 percent, or $2.28, to $26.44 in afternoon trading. So Lankau's decision to resign is adding $300 million to the Chadds Ford drug maker's market value.
